Zacks Industry Outlook McKesson, Cardinal, West Pharmaceutical, Align and Henry

Medical/dental supply stocks are framed as set up for 2H26 tailwinds, with the global medical supplies industry projected to reach $163.5B by 2027 (3.4% CAGR). The group outperformed its medical sector (+10.2% vs +9.6%) over the past year but lagged the S&P 500 (+24.2%), and trades at a lower forward P/E of 16.83x vs 21.23x for the S&P 500. Zacks highlights five “buy” candidates (MCK, CAH, WST, ALGN, HSIC; generally Zacks Rank #2) supported by AI/automation-enabled supply-chain upgrades and stronger specialty care demand, while warning of tariff-related cost pressures and policy-driven pricing reforms under lingering uncertainty through 2H26.

Analysis

This is less a broad healthcare-rally signal than a relative-value setup inside the supply/distribution stack. The best risk-adjusted beneficiaries are the scaled middlemen and specialty-heavy platforms, where incremental outpatient and oncology volume drops more cleanly to EBITDA than it does for product companies facing tariff pass-through and pricing pressure. That tilts favorably toward MCK and CAH; WST also benefits, but only if biologics/injectable demand stays above the inventory-normalization noise.

The weaker names are the ones where growth depends on discretionary dental capex or pricing power in a crowded channel. ALGN and HSIC face a tougher mix: even if procedure volumes hold, low-cost competition and channel price pressure can cap margin expansion, so positive volume trends may not translate into multiple expansion. In practice, AI/automation is a margin story first; until investors see hard evidence in SG&A, fulfillment, and working-capital turns, the market should treat it as an execution claim, not a demand inflection.

Catalyst path is mostly 1-3 months: next earnings prints and guidance revisions matter more than the promotional tone of the note. The contrarian view is that the market may already be assuming a smooth second-half setup, while tariff leakage and dental equipment deflation can quietly offset the supposed tailwinds. Over 6-18 months, the structural outpatient shift remains real, but the cheaper way to express it is through scale distributors and workflow-enablers rather than the more commoditized dental hardware names.

Key Decisions for Investors

• Long MCK / short HSIC as a relative-value pair into the next earnings cycle; thesis is specialty-distribution mix and automation-driven operating leverage versus dental pricing pressure. Target 5-8% relative outperformance over 1-3 months; cut if HSIC shows clear gross-margin stabilization or MCK misses specialty growth assumptions.
• Long CAH / short ALGN for a cleaner beneficiary-vs-pricing-pressure trade. CAH has more direct exposure to specialty/pharma mix and decentralized care; ALGN is more exposed to scanner competition and discretionary demand sensitivity. Use as a 2-3 month pair around earnings revisions.
• Add WST on weakness, but only as a selective 6-12 month hold or call spread, not a chase-buy. Thesis depends on sustained biologics and injectable uptake; invalidate if customer inventory normalization persists another quarter or management trims capacity/utilization expectations.
• Avoid a broad basket long of the whole group here; the signal is too modest for index-style risk. If you need sector exposure, prefer XLV over IYH-style higher-beta healthcare until tariff and pricing-policy visibility improves.